Core Insights - Autonomix Medical, Inc. is set to present final clinical data on its transvascular radiofrequency (RF) ablation approach for pain management in pancreatic adenocarcinoma at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases related to the nervous system [5] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The initial application of this technology is aimed at treating pain, particularly in pancreatic cancer, which is known for causing severe pain without reliable treatment options [6] Clinical Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation" has been accepted as an ePoster for the conference [2] - The ePoster will be presented by Dr. Clarke Wilkirson on February 6, 2026, during a dedicated session that includes a 10-minute presentation followed by a 5-minute discussion [3] Industry Context - The SIO Annual Scientific Meeting gathers leading clinicians, researchers, and innovators focused on advancing minimally invasive, image-guided therapies for cancer care [4] - The presentation at this conference highlights the potential of Autonomix's RF ablation approach to address significant unmet clinical needs in pain management for pancreatic cancer patients [4]